The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index.
Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats
Open accessAbstract
Significance: Mutations in the leucine-rich repeat kinase 2 ( LRRK2 ) gene are the most common known genetic cause of late-onset Parkinson disease, but the mechanisms underlying LRRK2 action in neurodegeneration are not clear. We demonstrate that rats deficient in LRRK2 expression are protected from dopaminergic neurodegeneration caused by overexpression of α-synuclein or exposure to LPS. LRRK2 expression is induced in proinflammatory brain myeloid cells under pathological conditions. Our results suggest that LRRK2 inhibition may have important neuroprotective effects by critically modulating neuroinflammatory responses. LRRK2 inhibition may therefore be a potentially efficacious approach to slow or stop the progression of brain disorders where myeloid cell activation drives aspects of dysfunction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LRRK2-deficient rats, in contrast, had no significant loss of neurons and reduced numbers of activated myeloid cells in the substantia nigra (160).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [160]
Citations
Cites
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563 · cited 1×
“However, it is important to distinguish virally delivered human α-synuclein expression from emerging models of PD that harness transmissible α-synuclein fibrils (20).”
BackgroundGenomewide Association Study of Leprosy
Zhang, F.-R., Huang, W., Chen, S.-M., Sun, L.-D., Liu, H., Li, Y., Cui, Y., Yan, X.-X., Yang, H.-T., Yang, R.-D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903753 · Cited by 1,031
The myeloid cells of the central nervous system parenchyma
Ransohoff, R. M., & Cardona, A. E. (2010) · Nature · doi:10.1038/nature09615 · Cited by 804 · cited 1×
“A shift from ramified to amoeboid morphologies of ionized calciumbinding adapter molecule 1 (Iba1)/CD68-positive cells is indicative of myeloid cell activation (15).”
BackgroundToll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia
Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G. K., & Stefanova, N. (2013) · Glia · doi:10.1002/glia.22437 · Cited by 697 · cited 1×
“Direct α-synuclein exposures to microglia cells have been described to activate many of the same responses (16).”
BackgroundLRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A. L., Klein, C., Henick, B., Hailpern, S. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055509 · Cited by 665 · cited 1×
“Notably, these mutations are prevalent in the Ashkenazi Jewish and North African Arab Berber populations in more than 20% of PD cases (1, 2).”
BackgroundKirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649 · cited 3×
“α-synuclein overexpression in the SNpc using recombinant adeno-associated virus (rAAV) has been previously found to produce a selective and relatively robust lesion of dopaminergic neurons, comparable to the level of neurodegeneration induced by LPS exposure (12, 13).”
BackgroundThe role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539 · cited 1×
“The discovery of potent and specific small molecule inhibitors that are near ready for implementation in vivo should allow for future translation to clinical applications (21).”
BackgroundLin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.-X., Yang, W.-J., Ding, J., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.006 · Cited by 518
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463 · cited 5×
“RNA-interference knockdown of LRRK2 reduces immune responses induced by the toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS) (10).”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 1
- 10.1371/journal.pgen.1001195 · DOI
Cited by
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Oxidative stress and Parkinson’s disease
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878
“LRRK2 increases proinflammatory cytokine release from activated primary microglial cells which results in neurotoxicity (Gillardon et al., 2012).”
BackgroundInfluentialInflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
LRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Metadata
- Authors
- Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S., & West, A. B.
- Affiliations
- University of Alabama at Birmingham (US)
- Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-06-09
- Volume
- 111
- Issue
- 25
- Pages
- 9289-9294
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4078806
- OpenAlex
- W2053206193
- Cited by
- 223
- References
- 24
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 9 · 2023: 19 · 2022: 18 · 2021: 26 · 2020: 24 · 2019: 17 · 2018: 28 · 2017: 19 · 2016: 17 · 2015: 18 · 2014: 7
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (F31NS081963, R01NS064934)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- LRRK2, alpha-synuclein, Parkinson's disease, dopaminergic neuron loss, neuroinflammation, myeloid cells, substantia nigra, lipopolysaccharide, inducible nitric oxide synthase, neuroprotection, AAV gene delivery
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Animals, Humans, Lipopolysaccharides, Substantia Nigra, Protein Serine-Threonine Kinases, Neurodegenerative Diseases, Myeloid Cells, Rats, alpha-Synuclein, Nitric Oxide Synthase Type II, Rats, Transgenic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats. https://app.cochat.ai/papers/10.1073/pnas.1403215111
- The paper
- Daher, J. P. L., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S., & West, A. B. (2014). Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1403215111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.